Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States

PURPOSE: In the Phase III COV-BARRIER (Efficacy and Safety of Baricitinib for the Treatment of Hospitalised Adults With COVID-19) trial, treatment with baricitinib, an oral selective Janus kinase 1/2 inhibitor, in addition to standard of care (SOC), was associated with significantly reduced mortalit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohsfeldt, Robert, Kelton, Kari, Klein, Tim, Belger, Mark, Mc Collam, Patrick L., Spiro, Theodore, Burge, Russel, Ahuja, Neera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2021
Materias:
COVID Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487786/
https://www.ncbi.nlm.nih.gov/pubmed/34732289
http://dx.doi.org/10.1016/j.clinthera.2021.09.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487786/
https://www.ncbi.nlm.nih.gov/pubmed/34732289
http://dx.doi.org/10.1016/j.clinthera.2021.09.016

Ejemplares similares